Brian T. Burgess, DO, first-year fellow, University of Kentucky Markey Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.
Brian T. Burgess, DO
Advertisement
Articles by Brian T. Burgess, DO
Advertisement
Latest Updated Articles
Dr. Burgess on PARP Resistance in Ovarian CancerPublished: September 25th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5